Immunologic Agents : Active Immunity (Vaccines and Toxoids)
ICERV1 “CervarixTM injection” 0.5 ml/syringe
IGARD1 “Gardasil injection” 0.5 ml/syringe
適應症：
ICERV1：適用於為10歲至25歲的女性接種，藉以預防致癌性人類乳突病毒(HPV)第16型與第18型所引起的偶發性及持續性感染、與子宮頸上皮內贅瘤、及癌前病變，從而預防子宮頸癌。
IGARD1：9-26歲女性之預防接種；疫苗所含的人類乳突病毒四型（第六、十一、十六及十八）所引起的子宮頸癌前期，或分化不良的病變和癌症、陰道及外陰部癌前期，或分化不良的病變、生殖器疣（俗稱菜花）。
Usual dose: IM
0.5 ml in the deltoid region of the upper arm or in the higher anterolateral area of the thigh, according to the following schedule: 1st dose: At elected date; 2nd dose: 2 mon after the 1st dose; 3rd dose: 6 mon after the 1st dose.
Precaution:
Immunosuppressed or immunodeficient p’ts; expected immune response may not be obtained.
Persons with bleeding disorders (intramuscular injection); use not recommended unless potential benefit justifies risk.
Treatment of active genital warts, cervical cancer, cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, and vaginal intraepithelial neoplasia; use not recommended.
Adverse effect:
Injection site reactions, fever, nausea, dizziness.